Biosimilar pegfilgrastim regulatory update

Coherus submitted a BLA to FDA for CHS-1701, a biosimilar of neutropenia drug Neulasta pegfilgrastim. Coherus plans to submit an MAA next quarter to EMA for the biosimilar. Amgen Inc. (NASDAQ:AMGN, ...